Kumagai Koichiro, Tojo Hideaki, Noguchi Hiroo, Yasuda Tomoo, Ogawa Masahiro, Nakashima Hideko, Zhang Bo, Saku Keijiro
Department of Cardiology, Fukuoka University Hospital, Fukuoka, Japan.
J Cardiovasc Electrophysiol. 2004 Dec;15(12):1396-401. doi: 10.1046/j.1540-8167.2004.04430.x.
Na+ channel blockers are used to treat atrial fibrillation (AF). However, the effects of Na+ channel blockers on the electrophysiologic properties of pulmonary veins (PVs) are not well characterized. The aim of the present study was to evaluate the effect of the pure Na+ channel blocker pilsicainide on the PVs.
PV mapping using a basket catheter was performed in 28 patients with paroxysmal AF. Twenty-eight PVs, including 20 left superior and 8 right superior PVs, were studied. Programmed stimulation was performed in the distal PV and PV-left atrial (LA) junction before and after infusion of pilsicainide (1 mg/kg). Pilsicainide significantly prolonged the effective refractory period (ERP) of the distal PV from 163 +/- 44 msec to 192 +/- 53 msec (P < 0.001), PV-LA junction from 227 +/- 48 msec to 235 +/- 52 msec (P < 0.05), and LA appendage from 225 +/- 55 msec to 245 +/- 48 msec (P < 0.05). Pilsicainide significantly prolonged the conduction time from the distal PV to PV-LA junction from 45 +/- 14 msec to 70 +/- 26 msec (P < 0.0001). In 3 of 5 patients who experienced AF termination with pilsicainide, PV-LA conduction block was observed just before AF termination.
Pilsicainide can modify ERP heterogeneity and conduction properties in the PV and at the PV-LA junction. Because the PV and PV-LA junction have important roles as substrates for AF maintenance, pilsicainide may terminate AF by pharmacologic PV isolation.
钠离子通道阻滞剂用于治疗心房颤动(AF)。然而,钠离子通道阻滞剂对肺静脉(PVs)电生理特性的影响尚未得到充分阐明。本研究的目的是评估纯钠离子通道阻滞剂吡西卡尼对肺静脉的作用。
对28例阵发性房颤患者使用篮状导管进行肺静脉标测。研究了28条肺静脉,包括20条左上肺静脉和8条右上肺静脉。在输注吡西卡尼(1mg/kg)前后,在肺静脉远端和肺静脉-左心房(LA)交界处进行程控刺激。吡西卡尼显著延长了肺静脉远端的有效不应期(ERP),从163±44毫秒延长至192±53毫秒(P<0.001),肺静脉-左心房交界处从227±48毫秒延长至235±52毫秒(P<0.05),左心耳从225±55毫秒延长至245±48毫秒(P<0.05)。吡西卡尼显著延长了从肺静脉远端到肺静脉-左心房交界处的传导时间,从45±14毫秒延长至70±26毫秒(P<0.0001)。在5例使用吡西卡尼终止房颤的患者中,有3例在房颤终止前观察到肺静脉-左心房传导阻滞。
吡西卡尼可改变肺静脉及肺静脉-左心房交界处的ERP异质性和传导特性。由于肺静脉及肺静脉-左心房交界处作为房颤维持的基质具有重要作用,吡西卡尼可能通过药物性肺静脉隔离来终止房颤。